TR200100021T2 - Kandaki yağ değerlerini etkileyen en az bir etki maddesine sahip bileşim - Google Patents

Kandaki yağ değerlerini etkileyen en az bir etki maddesine sahip bileşim

Info

Publication number
TR200100021T2
TR200100021T2 TR2001/00021T TR200100021T TR200100021T2 TR 200100021 T2 TR200100021 T2 TR 200100021T2 TR 2001/00021 T TR2001/00021 T TR 2001/00021T TR 200100021 T TR200100021 T TR 200100021T TR 200100021 T2 TR200100021 T2 TR 200100021T2
Authority
TR
Turkey
Prior art keywords
active ingredient
composition
blood fat
affects blood
fat values
Prior art date
Application number
TR2001/00021T
Other languages
English (en)
Inventor
Berthold Achim
Original Assignee
Lts Lohmann Therapie-Systeme Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lts Lohmann Therapie-Systeme Ag filed Critical Lts Lohmann Therapie-Systeme Ag
Publication of TR200100021T2 publication Critical patent/TR200100021T2/tr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
    • A61K9/703—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms characterised by shape or structure; Details concerning release liner or backing; Refillable patches; User-activated patches
    • A61K9/7038—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer
    • A61K9/7046—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds
    • A61K9/7053—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds obtained by reactions only involving carbon to carbon unsaturated bonds, e.g. polyvinyl, polyisobutylene, polystyrene
    • A61K9/7061—Polyacrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A61K31/366—Lactones having six-membered rings, e.g. delta-lactones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
    • A61K9/703—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms characterised by shape or structure; Details concerning release liner or backing; Refillable patches; User-activated patches
    • A61K9/7038—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer
    • A61K9/7046—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds
    • A61K9/7069—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds obtained otherwise than by reactions only involving carbon to carbon unsaturated bonds, e.g. polysiloxane, polyesters, polyurethane, polyethylene oxide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers

Abstract

Bir organizmanin kan yag degerlerini etkileyen en az bir etki maddesi içeren preparatin özelligi, etki maddesi geçirmeyen bir arka tabaka tabaka ile kapatilan, kendiliginden yapisan bir matris tabakasinin cilde dönük olmayan tarafinda içeren bir transdermal terapi flasteri seklinde olmasidir.
TR2001/00021T 1998-07-09 1999-07-07 Kandaki yağ değerlerini etkileyen en az bir etki maddesine sahip bileşim TR200100021T2 (tr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE19830732A DE19830732B4 (de) 1998-07-09 1998-07-09 Zusammensetzung, enthaltend mindestens einen die Blutfettwerte beeinflussenden Wirkstoff und seine Verwendung

Publications (1)

Publication Number Publication Date
TR200100021T2 true TR200100021T2 (tr) 2001-05-21

Family

ID=7873488

Family Applications (1)

Application Number Title Priority Date Filing Date
TR2001/00021T TR200100021T2 (tr) 1998-07-09 1999-07-07 Kandaki yağ değerlerini etkileyen en az bir etki maddesine sahip bileşim

Country Status (22)

Country Link
EP (1) EP1094797B1 (tr)
JP (1) JP2002520272A (tr)
KR (1) KR100549848B1 (tr)
CN (1) CN1309377C (tr)
AR (1) AR019902A1 (tr)
AT (1) ATE278395T1 (tr)
AU (1) AU770573B2 (tr)
BR (1) BR9911941A (tr)
CA (1) CA2336712C (tr)
CZ (1) CZ300976B6 (tr)
DE (2) DE19830732B4 (tr)
ES (1) ES2230872T3 (tr)
HU (1) HU226614B1 (tr)
IL (2) IL140667A0 (tr)
MX (1) MXPA01000126A (tr)
NZ (1) NZ509215A (tr)
PL (1) PL194983B1 (tr)
RU (1) RU2227023C2 (tr)
TR (1) TR200100021T2 (tr)
TW (1) TWI237572B (tr)
WO (1) WO2000002541A1 (tr)
ZA (1) ZA200100171B (tr)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL189890B1 (pl) * 1999-09-14 2005-10-31 Kazmierski Jan Zaklad Prod Usl Preparat do ochrony roślin przed chorobami
WO2004026297A1 (ja) * 2002-09-20 2004-04-01 Kowa Co., Ltd. 外用剤
JP2006515026A (ja) * 2003-01-02 2006-05-18 フェムファーマ ホールディング カンパニー， インコーポレイテッド 乳房の疾患および障害の処置のための薬学的調製物
US9173836B2 (en) 2003-01-02 2015-11-03 FemmeParma Holding Company, Inc. Pharmaceutical preparations for treatments of diseases and disorders of the breast
US20070166360A1 (en) * 2004-03-31 2007-07-19 Kowa Co., Ltd. External preparation
JP4986411B2 (ja) * 2004-06-01 2012-07-25 久光製薬株式会社 貼付剤
US8173155B2 (en) 2004-06-01 2012-05-08 Hisamitsu Pharmaceutical Co., Inc. Adhesive patch
WO2006002127A1 (en) * 2004-06-21 2006-01-05 Fairfield Clinical Trials, Llc Transdermal delivery system for statin combination therapy
DE102004062182B4 (de) * 2004-12-20 2007-06-06 Bayer Schering Pharma Ag Transdermales Pflaster mit Progesteron A-Spezifische Liganden (PRASL) als Wirkstoff
US20090181098A1 (en) * 2006-03-07 2009-07-16 Osteoscreen Ip, Llc Hmg-Co-a Reductase Inhibitor Enhancement of Bone and Cartilage
KR100817274B1 (ko) * 2006-08-21 2008-03-27 삼성전기주식회사 발광 다이오드 패키지 및 그 제조방법
WO2018115535A1 (es) 2016-12-19 2018-06-28 Nutritape, S.L. Parche energizante para deportistas
WO2020185394A1 (en) 2019-03-12 2020-09-17 Corning Incorporated Ceramic honeycomb body with skin
TWI803052B (zh) * 2021-11-12 2023-05-21 佛教慈濟醫療財團法人 經皮遞送裝置及其使用及製造方法

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3634016A1 (de) * 1986-04-17 1987-10-29 Lohmann Gmbh & Co Kg Flaechenfoermiges therapeutisches system, verfahren zu seiner herstellung und seine verwendung
US5503844A (en) * 1993-05-18 1996-04-02 Mli Acquisition Corp. Ii Foam laminate transdermal patch
FR2719220A1 (fr) * 1994-04-29 1995-11-03 Lafon Labor Nouvelle forme galénique pour l'administration transdermique.
AU3618795A (en) * 1994-10-05 1996-05-02 Hisamitsu Pharmaceutical Co., Inc. Drug compounding ingredients comprising n-substituted-o-toluidine derivative and percutaneously absorbable preparation
DE19541260A1 (de) * 1995-11-06 1997-05-07 Lohmann Therapie Syst Lts Therapeutische Zubereitung zur transdermalen Applikation von Wirkstoffen durch die Haut
EP1028724A1 (en) * 1997-11-10 2000-08-23 Novo Nordisk A/S Transdermal delivery of 3,4-diarylchromans

Also Published As

Publication number Publication date
CN1309377C (zh) 2007-04-11
KR20010079513A (ko) 2001-08-22
CZ300976B6 (cs) 2009-09-30
KR100549848B1 (ko) 2006-02-06
ZA200100171B (en) 2001-08-10
IL140667A (en) 2007-05-15
CA2336712C (en) 2008-09-09
HUP0102718A2 (hu) 2002-03-28
HUP0102718A3 (en) 2002-12-28
PL345510A1 (en) 2001-12-17
HU226614B1 (en) 2009-04-28
DE19830732B4 (de) 2008-11-13
WO2000002541A1 (de) 2000-01-20
AU770573B2 (en) 2004-02-26
ES2230872T3 (es) 2005-05-01
AU5157499A (en) 2000-02-01
EP1094797A1 (de) 2001-05-02
IL140667A0 (en) 2002-02-10
CZ200193A3 (en) 2001-05-16
NZ509215A (en) 2003-04-29
CA2336712A1 (en) 2000-01-20
TWI237572B (en) 2005-08-11
RU2227023C2 (ru) 2004-04-20
EP1094797B1 (de) 2004-10-06
DE59910758D1 (de) 2004-11-11
JP2002520272A (ja) 2002-07-09
ATE278395T1 (de) 2004-10-15
BR9911941A (pt) 2001-03-27
CN1308525A (zh) 2001-08-15
PL194983B1 (pl) 2007-07-31
MXPA01000126A (es) 2002-06-04
AR019902A1 (es) 2002-03-20
DE19830732A1 (de) 2000-01-13

Similar Documents

Publication Publication Date Title
TR200100021T2 (tr) Kandaki yağ değerlerini etkileyen en az bir etki maddesine sahip bileşim
BRPI0417776A (pt) método de inibição da proliferação de uma pluralidade de células proliferativas, de inibição do crescimento de célula hospedeira em uma composição implantável em um humano e de inibição do crescimento celular em uma composição implantável em um animal, dispositivo implantável, método de inibição do crescimento celular em um dispositivo implantável, composição, e, métodos de preparação de um tecido artificial, de revestimento ou cobertura da superfìcie externa de uma composição ou dispositivo livre de células com uma uma matriz de alginato e de tratamento de um indivìduo que tem diabetes
ES2187785T3 (es) 3,5-difenil-1,2,4-triazoles sustituidos y su uso como queladores farmaceuticos de metales.
MY100066A (en) Multicompartmentalized dermal and transdermal patches.
BR0003897A (pt) Aditivo para aumento da resistência à água de formulações cosméticas ou dermatológicas e seus usos
DE60143360D1 (de) Zusammensetzung zur transdermalen und/oder transmukosalen Verabreichung von Wirkstoffen, die ausreichende therapeutische Spiegel garantiert
AR023715A1 (es) Composicion farmaceutica para un sujeto que necesita una elevacion del contenido de nad intracelular, y el uso de la misma para la manufactura de unmedicamento para aumentar las respuestas celulares protectoras al stress genotoxico en la piel
ATE293998T1 (de) Entzündungshemmendes kissen
ITMI20000095A0 (it) Cerotto per la somministrazione locale e transdermica di principi attivi dotati di gruppi anionici ed elettronattrattori
DE69943299D1 (de) Zubereitung mit langandauernder verlängerter arzneiwirkstofffreisetzung
DK474688D0 (da) Praeparat til bekaempelse af tumor eller kraeftceller
NO20002487D0 (no) Preparat med azelainsyre
ATE406897T1 (de) Kombination von et-743 mit 5-fluorouracil pro- drugs zur behandlung von krebs
ATE284996T1 (de) Papiertuch enthaltend antivirale wirkstoffe die hautfreundlich sind
TW200505437A (en) Composition possessing autonomic nerve function regulating action and use thereof
BR0009771A (pt) Utilização de derivados de bisindóis indigóides capazes de penetrarem na membrana de células
WO2004052294A3 (en) Compositions and methods related to lipid:emodin formulations
BR9908713A (pt) Uso de selegilina ou desmetil-selegilina para tratamento de feridas, queimaduras e danos dermatológicos
EP1090635A3 (en) Use of ferulic acid for treating hypertension
DK0379933T3 (da) Superficielt behandlingssystem med indhold af et antineoplastisk aktivstof, især 5-fluoruracil
AR033965A1 (es) Uso de un antagonista de tnfalfa, para tratar o inhibir la lesion celular o la muerte de las celulas
TR199701617T1 (tr) Çiftliklerde üretilen baliklarda görülen parazitlerle mücadelede kullanilacak bir ajan.
ATE185067T1 (de) Estradiol-tts mit wasserbindenden zusätzen
DE59504233D1 (de) Estradiol-tts mit wasserbindenden zusätzen
TNSN03024A1 (fr) Composition sous forme d'emulsion appropriee pour le traitement de l'hyperhidrose et/ou bromhidrose plantaire